Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR TKIs in Adenoid Cystic Carcinoma
NCT04974866Phase 2Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in adenoid cystic carcinoma (ACC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Progression-Free Survival at 10 months. Started Jul 2021; status: recruiting.
02
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT04974866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974866.